New combo therapy aims to tackle tough sarcomas

NCT ID NCT07342322

Not yet recruiting Disease control Sponsor: First Affiliated Hospital of Guangxi Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing a new treatment for soft tissue sarcoma that combines a special type of radiation with immunotherapy and immune-boosting drugs. The goal is to see if this combination can shrink tumors and improve outcomes for people with advanced or recurrent sarcoma. The study plans to enroll 25 participants and is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Toripalimab (an immunotherapy drug) combined with spatially fractionated radiotherapy and immune-boosting drugs (GM-CSF and thymalfasin)
What this could lead to: If successful, this could offer a new treatment option for people with advanced soft tissue sarcoma that cannot be removed by surgery.
What could go wrong: This is a small, early-phase trial with only 25 people, so results may not apply to everyone. The combination therapy may cause significant side effects, and it is not yet known if it will improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA (STS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOFT TISSUE SARCOMA (STS)

Contacts and locations

Locations

the First Affiliated Hospital of Guangxi Medical University

Nanning, Guangxi, 530021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.